title: [Treatment of systemic vasculitis].
abstract: Progress in the treatment of systemic vasculitis have permitted a decrease of mortality but with an increase in iatrogenic morbidity. Steroids remain the cornerstone of the treatment but precise modalities and other concomitant treatments are depending upon the type of vasculitis. In most cases, systemic vasculitis are primary and the treatment, although important, is symptomatic. However, in some cases such as hepatitis B virus-induced polyarteritis nodosa or hepatitis C virus-induced cryoglobulinemia, the treatment can be etiologic and is directed against the antigen responsible for the systemic vasculitis. In the future, a better understanding of pathological mechanisms, particularly of etiologic factors, and new treatment such as monoclonal antibodies should increase the prognosis of systemic vasculitis.
authors.affiliation: Service de médecine interne, hôpital de La Pitié-Salpêtrière, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Cacoub
authors.forename: J C
authors.initials: JC
authors.lastname: Piette
authors.forename: C
authors.initials: C
authors.lastname: Veyssier
authors.forename: B
authors.initials: B
authors.lastname: Wechsler
authors.forename: P
authors.initials: P
authors.lastname: Godeau
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010951:Plasma Exchange; D014657:Vasculitis / Q000188:drug therapy / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents
vernacular_title: Traitement des vascularites systémiques.